Sentence examples for mutation status revealed from inspiring English sources

Despite this general similarity, a separate analysis of gains and losses and stratification of familial tumours according to their BRCA1/2 mutation status revealed some differences.

On the other hand, coevaluation of age and IDH1/IDH2 mutation status revealed predictive value of IDH1/IDH2 only in the group of patients below 56 years of age).

Subclassification of MSI-H colon cancer patients according to B2M mutation status revealed that B2M wild-type MSI-H colon cancer patients were comparable to MSS colon cancer patients with regard to TTR.

Survival endpoints according to K-ras mutation status revealed a median PFS of 9.7 months in patients with K-ras wild-type tumours (n=22) and 10.4 months in patients with K-ras mutated tumours (n=14), and median OS of 26.7 and 24.1 months, respectively.

99,100 A comparison of the traditional clinicopathologic melanoma classification with a classification based on the somatic mutation status reveals remarkable similarities.

The analysis of NRAS gene status revealed 14 mutated cases, 13 mutations affected codon 61 (7 p.Q61R, 4 p.Q61K, 2 p.Q61H) and 1 affected codon 13 (p.Q13R).

Laser catapult microdissection and DNA isolation from the normal epithelium, dysplasia, and carcinoma components of each case were performed, and genetic analysis of TP53 status revealed a missense mutation in all three p53-immunopositive cases (Figure 2E; Supplemental Table S2).

Prior analysis of 20 human mesothelioma cell lines for p53 status revealed only two mutations and one p53 null cell line, although p53 expression was detected in most cell lines.

However, we envision that new techniques for analysis of additional aspects such as histone modification states and gene mutation status will reveal mechanisms that would explain even more gene expression changes within individual samples.

Stratification by BRCA1/ 2 status revealed no significant difference, although differences vs controls appeared greater for BRCA1-mutation carriers, most notably for P and OPG.

This implies that for older patients, KRAS and BRAF mutation status alone will reveal 98% of the patients unsuitable for anti-EGFR therapy, as compared to 71% in patients <50 years.